This variant can alter the efficiency of PIGR to release the Epstein–Barr virus immunoglobulin A (IgA-EBV) complex and consequently increase the susceptibility of populations in endemic areas to develop NPC (13). The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.